



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/627,631  
First Named Inventor : Marc G. ACHEN  
Filed : July 28, 2003  
TC/A.U. : 1645  
Examiner : P.N. Huynh

Confirmation No. : 3314

Docket No. : 029065.48666C1  
Customer No. : 23911

Title : Methods for Treating Neoplastic Disease Characterized by  
Vascular Endothelial Growth Factor D Expression, for  
Screening for Neoplastic Disease or Metastatic Risk, and  
for Maintaining Vascularization of Tissue

**AMENDMENT AFTER FINAL UNDER 37 C.F.R. §1.116**

**Mail Stop AF**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria , VA 22313-1450

Sir:

The following proposed amendments and remarks are respectfully submitted in response to the final Office Action dated January 12, 2006. It is believed that this Reply is timely filed on or before July 12, 2006, with a three month extension of time. Notwithstanding, should this Reply not be considered timely filed, Applicants hereby request a retroactive extension of time to file for the number of months required to maintain pendency of the Application.

Claims 8-27 and 36-44 are currently pending in this application. Claims 8-27 and 36-44 stand rejected.

Claims 8-11, 13-21 and 36-44 stand rejected under 35 U.S.C. 103(a) for allegedly being unpatentable over WO/9933485 in view of Achen *et al* (Eur J Biochem 267: 2505-2515, May 2000).

DCIWDMS: 2788072\_1